Lotte Tour Development Co., Ltd. (032350.KS)
KRW 7970.0
(-1.85%)
KRW 7970.0
(-1.85%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 313.54 Billion | 183.67 Billion | 107.07 Billion | 16.76 Billion | 88.44 Billion | 76.07 Billion |
| Cost of Revenue | - | 178.94 Billion | 151.69 Billion | 16.49 Billion | 65.64 Billion | 44.17 Billion |
| Gross Profit | 313.54 Billion | 4.72 Billion | -44.62 Billion | 270.28 Million | 22.8 Billion | 31.9 Billion |
| Operating Expenses | 374.15 Billion | 302.39 Billion | 238.32 Billion | 71.65 Billion | 38.95 Billion | 28.9 Billion |
| Selling, General and Administrative Expenses | 160.69 Billion | 133.52 Billion | 91.44 Billion | 16.72 Billion | 11.18 Billion | 10.28 Billion |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 213.45 Billion | 168.86 Billion | 146.87 Billion | 54.92 Billion | 27.76 Billion | -247.41 Million |
| Cost and Expenses | 374.15 Billion | 302.39 Billion | 238.32 Billion | 88.15 Billion | 104.6 Billion | 73.07 Billion |
| Operating Income | -60.6 Billion | -118.71 Billion | -131.25 Billion | -71.38 Billion | -16.15 Billion | 3 Billion |
| Interest Expense | 114.04 Billion | 92.76 Billion | 63.96 Billion | 9.2 Billion | 1.11 Billion | 117.33 Million |
| Income Tax Expense | -11.06 Billion | 670.32 Million | -7.69 Billion | 527.41 Million | 2.48 Billion | -3.59 Billion |
| Earnings before Tax | -213.39 Billion | -224.03 Billion | -208.39 Billion | -81.54 Billion | -11.61 Billion | -101.72 Billion |
| Net Income | -202.22 Billion | -224.7 Billion | -200.69 Billion | -82.06 Billion | -14.09 Billion | -108.46 Billion |
| Earnings Per Share Basic | -2721.40 | -3136.22 | -2897.06 | -1184.67 | -206.31 | -2199.00 |
| Earnings Per Share Diluted | -2721.40 | -3136.22 | -2897.06 | -1184.67 | -202.04 | -2199.00 |
| Weighted Average Shares Outstanding | 74.3 Million | 71.64 Million | 69.27 Million | 69.27 Million | 68.31 Million | 49.32 Million |
| Weighted Average Shares Outstanding (Diluted) | 74.3 Million | 71.64 Million | 69.27 Million | 69.27 Million | 69.75 Million | 49.32 Million |
| Gross Margin | 1.00 | 0.03 | -0.42 | 0.02 | 0.26 | 0.42 |
| EBIT Margin | -0.04 | -0.27 | -0.65 | -3.25 | -0.07 | 0.05 |
| Profit Margin | -0.64 | -1.22 | -1.87 | -4.89 | -0.16 | -1.43 |
| EBITDA | -13.18 Billion | -48.16 Billion | -75.26 Billion | -54.36 Billion | -8.85 Billion | -100.55 Billion |
| Earnings Before Tax Margin | -0.19 | -0.65 | -1.23 | -4.26 | -0.18 | 0.04 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 116.07 Billion | 106.22 Billion | 313.54 Billion | 92.72 Billion | 96.77 Billion | 76.93 Billion |
| Cost of Revenue | 51.51 Billion | 49.32 Billion | 196.85 Billion | 52.68 Billion | 49.7 Billion | 48.4 Billion |
| Gross Profit | 64.56 Billion | 56.9 Billion | 116.68 Billion | 40.03 Billion | 47.06 Billion | 28.52 Billion |
| Operating Expenses | 58.68 Billion | 48.1 Billion | 177.29 Billion | 49.33 Billion | 96.95 Billion | -95.18 Billion |
| Selling, General and Administrative Expenses | 44 Billion | 35.52 Billion | - | 49.33 Billion | 50.02 Billion | 95.18 Billion |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | -14.68 Billion | -12.58 Billion | -30.62 Billion | -1.62 Million | 123.76 Million | -190.37 Billion |
| Cost and Expenses | 110.19 Billion | 97.43 Billion | 374.15 Billion | 102.02 Billion | 96.95 Billion | -95.18 Billion |
| Operating Income | 5.88 Billion | 8.79 Billion | -60.6 Billion | -9.29 Billion | 340.67 Million | -18.24 Billion |
| Interest Expense | 38.3 Billion | 36.55 Billion | 114.04 Billion | 31.55 Billion | 28 Billion | 28.04 Billion |
| Income Tax Expense | -32.71 Billion | 5.09 Billion | -11.06 Billion | -11.15 Billion | -686.02 Million | 640.81 Million |
| Earnings before Tax | -35.99 Billion | -32.96 Billion | -213.98 Billion | -43.19 Billion | -30.18 Billion | -47.17 Billion |
| Net Income | -2.49 Billion | -38.38 Billion | -202.22 Billion | -31.25 Billion | -29.43 Billion | -47.78 Billion |
| Earnings Per Share Basic | -32.70 | -504.00 | - | -412.46 | -390.00 | -647.85 |
| Earnings Per Share Diluted | -32.70 | -504.00 | - | -412.46 | -390.00 | -647.85 |
| Weighted Average Shares Outstanding | 76.19 Million | 76.15 Million | 74.3 Million | 75.77 Million | 75.47 Million | 73.76 Million |
| Weighted Average Shares Outstanding (Diluted) | 76.19 Million | 76.15 Million | 74.3 Million | 75.77 Million | 75.47 Million | 73.76 Million |
| Gross Margin | 0.56 | 0.54 | 0.37 | 0.43 | 0.49 | 0.37 |
| EBIT Margin | 0.23 | 0.27 | - | 0.13 | 0.20 | 1.00 |
| Profit Margin | -0.02 | -0.36 | -0.64 | -0.34 | -0.30 | -0.62 |
| EBITDA | 27.22 Billion | 29 Billion | - | 12.33 Billion | 19.79 Billion | 76.93 Billion |
| Earnings Before Tax Margin | 0.05 | 0.08 | -0.19 | -0.10 | 0.00 | -0.24 |
DIABIO
GENPHARMA
GATE
GGAAF
QBAT
HBIE